A Phase 2 interventional study of Ribupatide and Placebo in Obesity, sponsored by Kailera. Active, not recruiting at 35 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Kailera · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing ribupatide in Obesity — 2 open to participants now, 9 under way, 6 of them phase 3. ribupatide · Obesity.
Among the 16 studies testing ribupatide in Obesity, this one is the 6th largest by enrollment, is one of 3 that started in 2026, is one of 4 in phase 2, and was the 15th registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →2 of the 16 studies testing ribupatide in Obesity are open now, in 2 countries. Recruiting first, the newest first:
Kailera · Sites in United States
Ages 18–85 · Healthy volunteers
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2023; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 264 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 142 across the 16 interventional studies. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 16 have an industry lead sponsor. The 3 most frequent:
Kailera is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Kailera has 9 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
4 of the studies testing ribupatide in Obesity that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06994650Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy | 2026-12 |
| NCT06974851Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity | 2026-12 |
| NCT07285902Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity | 2027-03 |
| NCT07458269KaileraEfficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes | 2027-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies testing ribupatide in Obesity, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to determine the effects of ribupatide administered by subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Additional inclusion/exclusion criteria may apply, per protocol.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Dose 1 of ribupatide once weekly.
Drug: Ribupatide
Participants will receive Dose 2 of ribupatide once weekly.
Drug: Ribupatide
Participants will receive Dose 3 of ribupatide once weekly.
Drug: Ribupatide
Participants will receive Dose 4 of ribupatide once weekly.
Drug: Ribupatide
Participants will receive placebo matched to ribupatide once weekly.
Drug: Placebo
SC Injection
Also known as: KAI-9531
SC Injection
Percent Change From Baseline in Body Weight at Week 48
Time frame: Baseline, Week 48
Percent of Participants with ≥5%, ≥10%, ≥15%, ≥20% and ≥25% Reduction From Baseline in Body Weight
Time frame: Baseline, Week 48
Change From Baseline in Waist Circumference
Time frame: Baseline, Week 48
Change From Baseline in Absolute Body Weight
Time frame: Baseline, Week 48
Change From Baseline in Body Mass Index (BMI)
Time frame: Baseline, Week 48
Percent Change From Baseline in Fasting Triglycerides
Time frame: Baseline, Week 48
Percent Change From Baseline in Fasting High-density Lipoprotein (HDL)-cholesterol
Time frame: Baseline, Week 48
Percent Change From Baseline in Fasting Non-HDL-cholesterol
Time frame: Baseline, Week 48
Percent Change From Baseline in Fasting Total Cholesterol
Time frame: Baseline, Week 48
Percent Change From Baseline in Fasting Low-density Lipoprotein (LDL)-cholesterol
Time frame: Baseline, Week 48
Percent Change From Baseline in Fasting Very Low-density Lipoprotein (VLDL)-cholesterol
Time frame: Baseline, Week 48
Percent Change From Baseline in Fasting Insulin
Time frame: Baseline, Week 48
Change From Baseline in Fasting Blood Glucose
Time frame: Baseline, Week 48
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame: Day 1 up to Week 52
Number of Participants With Anti-drug Antibodies (ADAs)
Time frame: Day 1 up to Week 52
Number of Participants With Neutralizing Antibodies (NAbs)
Time frame: Day 1 up to Week 52
Plasma Concentrations of Ribupatide
Time frame: Day 1 up to Week 52
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for May 2027, 14 months after the start.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 14 months is above that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ribupatide
Kailera